Health News

Scancell Holdings Plc, the developer of therapeutic cancer vaccines, announces that a treatment utilising a DNA vaccine based on its ImmunoBody® technology, in combination with ImmuneRegen BioSciences, Inc.®’s lead compound, Homspera®, has significantly improved the immune response of the vaccine in an animal model. Follow-up studies are currently being performed to optimize the effects of Homspera in enhancing the next generation of Scancell’s cancer vaccines.

Read more

Filed under: Pharmacy News
Tags: cancer, DNA, Pharmacy

Related posts

• ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer (0)
  ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate. Read more [tags] Pharmacy News [/tags]
  
  
• ZIOPHARM receives European patent allowance for palifosfamide to treat cancer (0)
  ZIOPHARM Oncology, Inc. announced today that it has received an allowance from the European Patent Office for Patent Application No. 05 821 125.1, entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to pharmaceutical compositions of a novel DNA cross-linker, including palifosfamide and their use in treating cancer. Read more [tags] Pharmacy [...]
  
  
• Vical’s Vaxfectin adjuvant boosts immune response of DNA-based vaccines against cancer (0)
  Vical Incorporated announced today that the company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models. Read more [tags] Pharmacy News [/tags]
  
  
• Vical Receives Milestone Payment From Merck & Co., Inc. Triggered By Planned Initiation Of Investigational Cancer DNA Vaccine Trial (0)
  Vical Incorporated (Nasdaq: VICL) announced the receipt of a $1.0 million milestone payment from Merck & Co., Inc. based on Merck's planned initiation of a Phase I clinical trial of an investigational plasmid DNA (pDNA) cancer vaccine. The candidate vaccine is based on Vical's DNA gene delivery technology and encodes human telomerase reverse transcriptase [...]
  
  
• VGX Pharmaceuticals Avian Influenza DNA Vaccine Delivered with Electroporation Provides 100% Protection of Non-Human Primates (0)
  VGX Pharmaceuticals Inc. (VGX), a leading developer of DNA vaccines and therapies for infectious diseases and cancer, announced today preclinical results indicating that its avian influenza DNA vaccine delivered using intramuscular or intradermal electroporation provided 100% protection of non-human primates against the H5N1 avian influenza virus. Read more [tags] Pharmacy News [/tags]